To amend title III of the Public Health Service Act to temporarily limit the use of rebates under the 340B Program.
Summary
HR10770, introduced on 2026-10-09, proposes to temporarily limit rebate use under the 340B Program. The bill is in early stage, referred to the House Committee on Energy and Commerce. No near-term market impact is expected, but drug manufacturers like Eli Lilly ($LLY) could face minor pricing adjustments if the bill advances.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR10770 is an early-stage bill with no near-term market impact.
- 2.The bill targets the 340B drug discount program, a complex area with ongoing policy debates.
- 3.Bipartisan cosponsorship indicates some legislative interest, but the path to enactment is long.
- 4.Drug manufacturers like Eli Lilly ($LLY) are potential stakeholders if the bill progresses.
Market Implications
No immediate market implications. The 340B program affects drug pricing dynamics, but this bill is too early in the legislative process to drive market movements. Investors should watch for committee hearings or markups that could clarify the bill's impact on manufacturers like $LLY.
Full Analysis
HR10770 was introduced in the House on October 9, 2026, by Rep. Bresnahan (R-PA) with three bipartisan cosponsors. The bill amends title III of the Public Health Service Act to temporarily limit the use of rebates under the 340B Program. The 340B Program requires drug manufacturers to provide outpatient drugs at discounted prices to eligible healthcare organizations. The specific limitation on rebates is not detailed in the bill title, but it likely addresses concerns about duplicate discounts or rebate stacking. The bill has been referred to the House Energy and Commerce Committee, which has jurisdiction over the 340B Program. No further action has been taken. As an early-stage authorization bill with no funding attached, the market impact is minimal at this point. The bipartisan sponsorship suggests some interest, but the bill faces a long legislative process including committee markup, floor votes, and potential Senate action. Investors should monitor committee hearings for more details on the proposed rebate limitation. If the bill advances, drug manufacturers like Eli Lilly ($LLY) could see minor adjustments in their 340B pricing strategies, but the impact is likely small relative to their overall revenue. Other large manufacturers like Johnson & Johnson ($JNJ) could also be affected, but the early stage makes specific impact assessment uncertain.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Temporary limitation on rebate use under the 340B Program
Who must act
Drug manufacturers participating in the 340B Program, including Eli Lilly
What happens
Limits the ability of covered entities to use rebates, potentially altering manufacturer pricing strategies and reducing net revenue from 340B sales if upfront discounts must be deepened.
Stock impact
Eli Lilly's pharmaceutical segment includes drugs covered by 340B. The impact on revenue is uncertain but likely small relative to total revenue of $34.1B.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
HELP Copays Act
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
To amend the Employee Retirement Income Security Act of 1974, title XXVII of the Public Health Service Act, and the Internal Revenue Code of 1986 to require health insurance coverage of drugs indicated for the treatment of autoimmune diseases and certain blood disorders.
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Wildlife Health Coordination and Zoonotic Disease Prevention Act of 2026
INSULIN Act of 2026
Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →